URGN News and Press, UroGen Pharma Ltd. From 06/14/24

2024-06-14 07:00:13 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $60.00 for URGN on 2024-06-14 06:14:00. The adjusted price target was set to $60.00. At the time of the announcement, URGN was trading at $17.5. The overall price target consensus is ...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 3.5% to $129.61 on volume of 255,610,868 shares Longeveron Inc. (LGVN) rose 48.6% to $2.69 on volume of 190,987,878 shares PROSHARES TRUST (SQQQ) fell 1.6% to $8.54 on volume of 116,711,722 shares Tesl...

UroGen Pharma Ltd. (NASDAQ: URGN) is one of today's top gainers. The company's shares have moved 39.94% on the day to $17.8. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RT...

2024-06-13 11:21:20 ET More on UroGen Pharma UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript UroGen: All Eyes On UGN-102 Urogen files patent suit against Teva over cancer therapy Seeking Alpha’s Quant Rating on UroGen Pharma Historic...

Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI, 75.9%, 87.1%) Side Effect Profile Consistent with Previous Clinical Trials of UGN-102 UroGen will Host a Virtual Event Today at 11:00 AM Eastern Time ...

-- Program to Highlight 12-Month Durability of Response Results from the Phase 3 ENVISION Pivotal Trial -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today shared addit...

- Presentation June 11, 2024 at 3:20 PM ET - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45 ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD Cowen 5 th Annual Oncology Innovation Summit...

2024-05-13 18:30:56 ET UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Don Kim - CFO Jeff...